Movement Alert｜Micot Pharma-B Falls 5.03% in Regular Trading, Profit-Taking Continues on Fifth Trading Day Post-IPO

Market Focus06-30

On June 30, Micot Pharma-B declined 5.03% in regular trading, trading at 36.36 HKD/share, with turnover of approximately 29.26 million HKD.

The stock listed on the Hong Kong Stock Exchange on June 24 at an IPO price of 18.20 HKD and surged 102.75% on its debut day. The Hong Kong public offering was oversubscribed approximately 1,181.46 times, and the share price reached as high as 40 HKD post-listing, more than doubling from the offer price. The rapid rally accumulated significant floating profits, and profit-taking pressure has persisted, with similar pullback patterns observed on June 26 and June 29.

As an 18A-listed pre-revenue biotech company, Micot Pharma's core product MT1013 remains in Phase III clinical trials, with commercialization not expected until early 2028, offering no near-term revenue contribution. The continued unwinding of early gains has driven the ongoing correction.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1189377327?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-30 15:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1189377327","market":"us","top_or_hot":-1,"title":"Movement Alert｜Micot Pharma-B Falls 5.03% in Regular Trading, Profit-Taking Continues on Fifth Trading Day Post-IPO","media":"Market Focus","content":"<p><p>On June 30, Micot Pharma-B declined 5.03% in regular trading, trading at 36.36 HKD/share, with turnover of approximately 29.26 million HKD.</p><p>The stock listed on the Hong Kong Stock Exchange on June 24 at an IPO price of 18.20 HKD and surged 102.75% on its debut day. The Hong Kong public offering was oversubscribed approximately 1,181.46 times, and the share price reached as high as 40 HKD post-listing, more than doubling from the offer price. The rapid rally accumulated significant floating profits, and profit-taking pressure has persisted, with similar pullback patterns observed on June 26 and June 29.</p><p>As an 18A-listed pre-revenue biotech company, Micot Pharma's core product MT1013 remains in Phase III clinical trials, with commercialization not expected until early 2028, offering no near-term revenue contribution. The continued unwinding of early gains has driven the ongoing correction.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Micot Pharma-B Falls 5.03% in Regular Trading, Profit-Taking Continues on Fifth Trading Day Post-IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Micot Pharma-B Falls 5.03% in Regular Trading, Profit-Taking Continues on Fifth Trading Day Post-IPO\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-30 15:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 30, Micot Pharma-B declined 5.03% in regular trading, trading at 36.36 HKD/share, with turnover of approximately 29.26 million HKD.</p><p>The stock listed on the Hong Kong Stock Exchange on June 24 at an IPO price of 18.20 HKD and surged 102.75% on its debut day. The Hong Kong public offering was oversubscribed approximately 1,181.46 times, and the share price reached as high as 40 HKD post-listing, more than doubling from the offer price. The rapid rally accumulated significant floating profits, and profit-taking pressure has persisted, with similar pullback patterns observed on June 26 and June 29.</p><p>As an 18A-listed pre-revenue biotech company, Micot Pharma's core product MT1013 remains in Phase III clinical trials, with commercialization not expected until early 2028, offering no near-term revenue contribution. The continued unwinding of early gains has driven the ongoing correction.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02335","symbol_name":"麦科医药-B","start_time":0,"source_url":"","article_id":"1189377327","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1189377327","pubTimestamp":1782805866,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 30, Micot Pharma-B declined 5.03% in regular trading, trading at 36.36 HKD/share, with turnover of approximately 29.26 million HKD.The stock listed on the Hong Kong Stock Exchange on June 24...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02335":"麦科医药-B"},"translate_title":"异动提示|Micot Pharma-B常规交易跌5.03%IPO后第五个交易日获利了结继续","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02335":1},"content_text":"On June 30, Micot Pharma-B declined 5.03% in regular trading, trading at 36.36 HKD/share, with turnover of approximately 29.26 million HKD.The stock listed on the Hong Kong Stock Exchange on June 24 at an IPO price of 18.20 HKD and surged 102.75% on its debut day. The Hong Kong public offering was oversubscribed approximately 1,181.46 times, and the share price reached as high as 40 HKD post-listing, more than doubling from the offer price. The rapid rally accumulated significant floating profits, and profit-taking pressure has persisted, with similar pullback patterns observed on June 26 and June 29.As an 18A-listed pre-revenue biotech company, Micot Pharma's core product MT1013 remains in Phase III clinical trials, with commercialization not expected until early 2028, offering no near-term revenue contribution. The continued unwinding of early gains has driven the ongoing correction.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1189377327","isCrawlerRequest":true}